Pfizer Inc. Stock Analysis: Oncology Growth and Valuation
Hyper Stocks ·
Pfizer’s stock has lagged for years, even after a huge Covid-era revenue surge. The key question now is whether oncology growth and new drugs can offset patent expirations.
Loading the full article…